Profil
Graham Parry worked as Biology Director at Attenuon, LLC and as Principal at Motility, Inc. He also worked as Vice President-Technical Operations at True North Therapeutics, Inc. from 2014 to 2017.
Parry received his undergraduate degree from Brunel University and his doctorate degree from the University of London.
Ehemalige bekannte Positionen von Graham Parry
| Unternehmen | Position | Ende |
|---|---|---|
True North Therapeutics, Inc.
 True North Therapeutics, Inc. BiotechnologyHealth Technology True North Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, and commercialization of first-in-class product candidates for complement-mediated diseases. The company was founded by Nancy E. Stagliano in 2013 and is headquartered in South San Francisco, CA. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2017 |
| Motility, Inc. | Corporate Officer/Principal | - |
| Attenuon, LLC | Corporate Officer/Principal | - |
Ausbildung von Graham Parry
| Brunel University | Undergraduate Degree |
| University of London | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
| Attenuon, LLC | |
| Motility, Inc. | |
True North Therapeutics, Inc.
True North Therapeutics, Inc. BiotechnologyHealth Technology True North Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, and commercialization of first-in-class product candidates for complement-mediated diseases. The company was founded by Nancy E. Stagliano in 2013 and is headquartered in South San Francisco, CA. | Health Technology |
